U.Okay. says Alzheimer’s medication Kisunla, Leqembi aren’t cost-effective
LONDON — A U.Okay. well being company reiterated on Thursday that the restricted advantages of a pair of recent Alzheimer’s medication don’t justify their excessive costs, which means the medicines gained’t be made out there via the Nationwide Well being Service.
The choice by the U.Okay.’s cost-effectiveness watchdog displays how well being authorities in numerous components of the world have taken totally different approaches with the medication, that are the primary to have proven they’ll sluggish the development of the illness however have stoked debate about simply how significant that progress is for sufferers and learn how to weigh their accompanying dangers and prices.
The medication — Eli Lilly’s Kisunla (also referred to as donanemab) and Biogen and Eisai’s Leqembi (lecanemab) — gained approval from U.Okay. regulators final yr, with the Medicines and Healthcare merchandise Regulatory Company discovering the advantages of the medication outweighed the dangers for sure sufferers.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
